Cargando…
Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
BACKGROUND: A quadrivalent split influenza vaccine IIV4-W against both influenza A and B viruses is urgently needed. METHODS: To evaluate the safety and immunogenicity of IIV4-W in people aged 3–60 years, 2400 participants recruited in a double-blind phase III trial and were randomly assigned to the...
Autores principales: | Huang, Xiaoyuan, Fan, Ting, Li, Li, Nian, Xuanxuan, Zhang, Jiayou, Gao, Xuefen, Zhao, Wei, Chen, Wei, Zhang, Zhaoqing, Yao, Zhihao, Han, Xixin, Shi, Jinrong, Wang, Ying, Bian, Haihe, Shi, Nianmin, Li, Xinguo, Duan, Kai, Li, Guohua, Yang, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621009/ https://www.ncbi.nlm.nih.gov/pubmed/35714276 http://dx.doi.org/10.1080/21645515.2022.2079924 |
Ejemplares similares
-
Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study
por: Fan, Renfeng, et al.
Publicado: (2021) -
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023) -
Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
por: Wei, Xia, et al.
Publicado: (2023) -
Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023) -
Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
por: Hadigal, Sanjay, et al.
Publicado: (2022)